Presentation is loading. Please wait.

Presentation is loading. Please wait.

Suggested approach to patients with dabigatran-associated bleeding

Published byJoleen Randall Modified over 6 years ago

Similar presentations

Presentation on theme: "Suggested approach to patients with dabigatran-associated bleeding"— Presentation transcript:

1 Suggested approach to patients with dabigatran-associated bleeding
Suggested approach to patients with dabigatran-associated bleeding. aPCC, activated prothrombin complex concentrate; CRRT, continuous renal replacement therapy; HD, hemodialysis; PCC, prothrombin complex concentrate; rFVIIa, recombinant factor VIIa. Suggested approach to patients with dabigatran-associated bleeding. aPCC, activated prothrombin complex concentrate; CRRT, continuous renal replacement therapy; HD, hemodialysis; PCC, prothrombin complex concentrate; rFVIIa, recombinant factor VIIa. Felix Knauf et al. CJASN 2013;8: ©2013 by American Society of Nephrology

Download ppt "Suggested approach to patients with dabigatran-associated bleeding"

Similar presentations

Pneumococcal pneumonia vaccinations, by unit affiliation.

Pneumococcal pneumonia vaccinations, by unit affiliation.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
J. W. Eikelboom, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z

J. W. Eikelboom, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Zaccaria Ricci, Claudio Ronco, Sergio Picardo  Kidney International 

Zaccaria Ricci, Claudio Ronco, Sergio Picardo  Kidney International 
Continuous renal replacement therapy in the critically ill patient

Continuous renal replacement therapy in the critically ill patient
Section 5: Dialysis Interventions for Treatment of AKI

Section 5: Dialysis Interventions for Treatment of AKI
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
Bleeding and management of coagulopathy

Bleeding and management of coagulopathy
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Arman Qamar et al. JACC 2018;71:

Arman Qamar et al. JACC 2018;71:
Hemodialysis patients represent a tiny subset of all patients with heart disease. Hemodialysis patients represent a tiny subset of all patients with heart.

Hemodialysis patients represent a tiny subset of all patients with heart disease. Hemodialysis patients represent a tiny subset of all patients with heart.
The Iranian model of living renal transplantation

The Iranian model of living renal transplantation

Similar presentations

Ads by Google